<SEC-DOCUMENT>0001437749-21-008332.txt : 20210405
<SEC-HEADER>0001437749-21-008332.hdr.sgml : 20210405
<ACCEPTANCE-DATETIME>20210405213248
ACCESSION NUMBER:		0001437749-21-008332
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210401
FILED AS OF DATE:		20210405
DATE AS OF CHANGE:		20210405

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Foster Karen A.
		CENTRAL INDEX KEY:			0001683151

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36362
		FILM NUMBER:		21807936

	MAIL ADDRESS:	
		STREET 1:		C/O BIOLIFE SOLUTIONS, INC.
		STREET 2:		3303 MONTE VILLA PARKWAY, SUITE 310
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOLIFE SOLUTIONS INC
		CENTRAL INDEX KEY:			0000834365
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				943076866
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3303 MONTE VILLA PARKWAY
		STREET 2:		SUITE 310
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254011400

	MAIL ADDRESS:	
		STREET 1:		3303 MONTE VILLA PARKWAY
		STREET 2:		SUITE 310
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOLIFE SOLUTION INC
		DATE OF NAME CHANGE:	20030113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CRYOMEDICAL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rdgdoc.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-04-01</periodOfReport>

    <issuer>
        <issuerCik>0000834365</issuerCik>
        <issuerName>BIOLIFE SOLUTIONS INC</issuerName>
        <issuerTradingSymbol>BLFS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001683151</rptOwnerCik>
            <rptOwnerName>Foster Karen A.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BIOLIFE SOLUTIONS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>3303 MONTE VILLA PARKWAY, SUITE 310</rptOwnerStreet2>
            <rptOwnerCity>BOTHELL</rptOwnerCity>
            <rptOwnerState>WA</rptOwnerState>
            <rptOwnerZipCode>98021</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>1</isOfficer>
            <officerTitle>Chief Quality Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-04-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>M</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>8797</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>74208</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-04-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>3414</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>36.53</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>70794</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the &quot;Plan&quot;) on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus.</footnote>
        <footnote id="F2">The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Karen Foster</signatureName>
        <signatureDate>2021-04-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
